Skip to main content
Clinical Trials/JPRN-C000000239
JPRN-C000000239
Completed
Phase 1

A phase I/II study of concurrent chemoradiation with irinotecan hydrochloride(CPT-11) and cisplatin(CDDP) for uterine cervical cancer. (KCOG 0328) - A phase I/II study of concurrent chemoradiation with CPT-11 and CDDP for uterine cervical cancer. (KCOG 0328)

Kansai Clinical Oncology Group (KCOG)0 sites18 target enrollmentSeptember 16, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
terine cervical cancer
Sponsor
Kansai Clinical Oncology Group (KCOG)
Enrollment
18
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 16, 2005
End Date
December 1, 2006
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Kansai Clinical Oncology Group (KCOG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Severe complications: a) infections, diarrhea (watery), ileus, interstistial pneumonitis, lung fibrosis, b) massive pleural effusion or ascites, c) uncontrollable diabetes mellitus, d) other complications which suffer from progressing study. 2\) Co\-existence of active other malignancies. 3\) The patients with prior radiotherapy whose treatment area of irradiation will be overlaid to ex\-treatment area. 4\) Pregnant or expected to be pregnant and breast feeding mother. 5\) Known severe hypersensitivity to agent. 6\) Whom the investigator think unappropriate as a candidate.

Outcomes

Primary Outcomes

Not specified

Similar Trials